We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exploring Analyst Estimates for PTC Therapeutics (PTCT) Q1 Earnings, Beyond Revenue and EPS
Read MoreHide Full Article
The upcoming report from PTC Therapeutics (PTCT - Free Report) is expected to reveal quarterly loss of -$0.31 per share, indicating a decline of 103.1% compared to the year-ago period. Analysts forecast revenues of $236.22 million, representing a decline of 79.9% year over year.
The current level reflects an upward revision of 19.2% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Given this perspective, it's time to examine the average forecasts of specific PTC Therapeutics metrics that are routinely monitored and predicted by Wall Street analysts.
It is projected by analysts that the 'Revenues- Net product revenue- Emflaza' will reach $23.56 million. The estimate suggests a change of -50.7% year over year.
The combined assessment of analysts suggests that 'Revenues- Net product revenue- Translarna' will likely reach $35.12 million. The estimate suggests a change of -59.3% year over year.
According to the collective judgment of analysts, 'Revenues- Royalty revenue' should come in at $49.33 million. The estimate indicates a change of +35.4% from the prior-year quarter.
Analysts expect 'Revenues- Net product revenue' to come in at $196.25 million. The estimate points to a change of +27.9% from the year-ago quarter.
Over the past month, PTC Therapeutics shares have recorded returns of -6.5% versus the Zacks S&P 500 composite's +10.3% change. Based on its Zacks Rank #3 (Hold), PTCT will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Exploring Analyst Estimates for PTC Therapeutics (PTCT) Q1 Earnings, Beyond Revenue and EPS
The upcoming report from PTC Therapeutics (PTCT - Free Report) is expected to reveal quarterly loss of -$0.31 per share, indicating a decline of 103.1% compared to the year-ago period. Analysts forecast revenues of $236.22 million, representing a decline of 79.9% year over year.
The current level reflects an upward revision of 19.2% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Given this perspective, it's time to examine the average forecasts of specific PTC Therapeutics metrics that are routinely monitored and predicted by Wall Street analysts.
It is projected by analysts that the 'Revenues- Net product revenue- Emflaza' will reach $23.56 million. The estimate suggests a change of -50.7% year over year.
The combined assessment of analysts suggests that 'Revenues- Net product revenue- Translarna' will likely reach $35.12 million. The estimate suggests a change of -59.3% year over year.
According to the collective judgment of analysts, 'Revenues- Royalty revenue' should come in at $49.33 million. The estimate indicates a change of +35.4% from the prior-year quarter.
Analysts expect 'Revenues- Net product revenue' to come in at $196.25 million. The estimate points to a change of +27.9% from the year-ago quarter.
View all Key Company Metrics for PTC Therapeutics here>>>Over the past month, PTC Therapeutics shares have recorded returns of -6.5% versus the Zacks S&P 500 composite's +10.3% change. Based on its Zacks Rank #3 (Hold), PTCT will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .